Novartis wants to amend invalidated patent for MS drug

Appeals 2019-07-02 1:30 pm By Amelia Birnie | Sydney

Please login to bookmark

Novartis has applied to amend its proposed patent for an oral form of multiple sclerosis drug Gilenya, as it appeals an invalidity ruling by IP Australia for lack of inventive step.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au